LEO Pharma’s topical JAK inhibitor cream Anzupgo (delgocitinib) became the first FDA-approved therapy specifically for chronic hand eczema in the U.S. Indicated for moderate to severe cases not responsive to corticosteroids, Anzupgo blocks inflammatory signaling proteins driving the disease. The approval comes months after EMA clearance, with the company scaling its U.S. sales force in preparation for launch. This addresses an unmet need affecting about 10% of adults globally, offering a steroid-free therapeutic alternative for chronic hand eczema sufferers.